Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts

Intratumour heterogeneity in the uptake of blood-borne technetium-labelled human serum albumin (Tc-99m-HSA) was studied in human melanoma xenografts in an attempt to identify transport barriers leading to inadequate and heterogeneous uptake of macromolecular therapeutic agents in tumours. The Bioscope imaging system, which can detect the distribution of Tc-99m in 10-mum-thick tissue sections with a spatial resolution of just above 50 mum, was used to image the Tc-99m-HSA uptake. Xenografted tumours of four human melanoma cell lines were included in the study. Significant intratumour heterogeneity in the uptake of Tc-99m-HSA was detected. The heterogeneity had two distinctly different components, one random and one radial component. The uptake was lowest in the centre of the tumours and increased towards the tumour periphery. This radial heterogeneity was superimposed by a random heterogeneity, that is, spots with high uptake colocalised with spots with high vascular density and regions without significant uptake colocalised with necrotic regions. The magnitude of the heterogeneity did not change significantly with time after the administration of Tc-99m-HSA. The tumours showed a random and a radial heterogeneity in blood perfusion similar to that in the uptake of Tc-99m-HSA. The observations reported here suggest that the intratumour heterogeneity in the distribution of Tc-99m-HSA was initiated primarily because of heterogeneity in the supply of Tc-99m-HSA through the microvasculature, and that the presence of severe transport barriers in the tumour interstitium prevented significant equalisation of the initial heterogeneity with time. Consequently, strategies for improving the delivery of macromolecular therapeutic agents to tumours should focus on increasing the tumour blood perfusion to increase the total uptake and improving the diffusion conditions in the tumour interstitium to diminish the heterogeneity in the uptake. (C) 2003 Cancer Research UK.